Aperio Receives Second Patent for Use of TDI Arrays in Microscope Slide Scanners.Digital Pathology Leader Broadens Patent Portfolio to Encompass Fluorescence fluorescence (fl  rĕs`əns), luminescence in which light of a visible color is emitted from a substance under stimulation or excitation by light or other forms of electromagnetic Imaging
VISTA, Calif. -- Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued the company patent No. 7,457,446 entitled "Fully Automatic Rapid Microscope Slide Scanner A scanner that is specialized for scanning 35mm slides and film negatives. The slide or film is inserted into a single slot in the machine or into a tray, which is inserted. Many flatbed scanners are also able to scan slides. See scanner and transparency adapter. ." U.S. patent 7,457,446 includes specific claims for the use of time delay integration (TDI TDI - Transport Driver Interface ) arrays in slide scanning systems, including the use of multiple TDI arrays in conjunction with a prism to split an optical signal into multiple color channels. "This is the second patent we have received in the last 60 days that covers the use of TDI arrays for whole slide imaging," said Dirk Soenksen, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Aperio. "Time delay integration is ideally suited for low light level applications such as fluorescence, and we're pleased that the '446 patent includes specific claims regarding the use of TDI arrays for fluorescence imaging." Aperio's patent portfolio encompasses all of the elements that comprise a digital pathology system, including digital slide creation, data management, advanced visualization, and image analysis. "Intellectual property will become more and more important as digital pathology becomes a critical technology in pathology laboratories," added Soenksen. "Our broad and growing patent portfolio provides us with the freedom to develop products to address current and future needs of our customers." Aperio holds over 30 issued patents and pending patent applications world-wide and is the digital pathology leader in the global market with an installed base of more than 450 systems in 28 countries. About Aperio Aperio is digitizing "Digitizer" redirects here. For the computer device, see Digitizing tablet. For the digitizer in Tablet PC's, see Tablet PC. Digitizing or digitization pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization dig·i·tize tr.v. dig·i·tized, dig·i·tiz·ing, dig·i·tiz·es To put (data, for example) into digital form. dig of a glass slide. Aperio's award-winning ScanScope[R] slide scanning systems and Spectrum[TM] digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research and image analysis. Aperio's products are FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information please visit www.aperio.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion